Ravi Jeevitha, Gunasekar Bhuvaneshwari, Basha Jamith
Department of Microbiology, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Thandalam, India.
Faculty of Applied Medical Sciences, Northern Border University, Arar, Saudi Arabia.
Microb Drug Resist. 2025 Jul;31(7):201-210. doi: 10.1089/mdr.2024.0117. Epub 2025 Jun 9.
The bacteria is encapsulated, rod-shaped, nonmotile, and Gram-negative bacilli. causes a variety of illnesses. They express various virulence factors such as capsules, which are primary virulence factors responsible for the pathogenicity and protection of bacteria from phagocytosis, lipopolysaccharide, which act as external membranes of the bacteria; and fimbriae-І and ІІІ which promote the binding to biological surfaces like medical devices such as ventilators. 's resistance to cephalosporins (3 and 4 generation), quinolones, carbapenem, and colistin is increasing. Colistin is the last trait to treat multidrug-resistant . The monotherapy is becoming ineffective to treat infections. Plasmid-borne genes called mediate colistin resistance, which is more prevalent. Colistin resistance and gene detection were done by using Epsilometry-test and conventional PCR, respectively. Amikacin was tested for synergism with colistin. Colistin with zinc oxide nanoparticle (NP) synergism was also tested. The properties of zinc oxide NPs are assessed by Fourier-transform infrared (FTIR), scanning electron microscope (SEM), and ultraviolet (UV) visible spectroscopy. Antibacterial activity of zinc oxide NPs was determined using the agar well diffusion method. In our study, we encourage combination drug therapy to treat the colistin-resistant . The synergistic activity of combined drugs was tested using checker-board technique. The results revealed that the synergistic activity of colistin combined with zinc oxide NPs and amikacin against colistin-resistant was found to be effective and can be further developed against the colistin resistant .
该细菌有荚膜，呈杆状，无运动性，为革兰氏阴性杆菌。可引发多种疾病。它们表达多种毒力因子，如荚膜，这是主要的毒力因子，负责细菌的致病性及保护细菌免受吞噬作用；脂多糖，其作为细菌的外膜；以及菌毛-Ⅰ和菌毛-Ⅲ，它们促进细菌与生物表面结合，如呼吸机等医疗设备。该细菌对头孢菌素（第三代和第四代）、喹诺酮类、碳青霉烯类和黏菌素的耐药性正在增加。黏菌素是治疗多重耐药该细菌的最后手段。单一疗法治疗感染正变得无效。名为的质粒携带基因介导黏菌素耐药性，这种情况更为普遍。分别使用E试验和常规聚合酶链反应进行黏菌素耐药性及基因检测。测试了阿米卡星与黏菌素的协同作用。还测试了黏菌素与氧化锌纳米颗粒（NP）的协同作用。通过傅里叶变换红外光谱（FTIR）、扫描电子显微镜（SEM）和紫外可见光谱对氧化锌纳米颗粒的特性进行评估。使用琼脂孔扩散法测定氧化锌纳米颗粒的抗菌活性。在我们的研究中，我们鼓励联合药物疗法来治疗耐黏菌素的该细菌。使用棋盘法测试联合药物的协同活性。结果显示，黏菌素与氧化锌纳米颗粒和阿米卡星联合对耐黏菌素的该细菌的协同活性被发现是有效的，并且可以针对耐黏菌素的该细菌进一步研发。
